Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* 12 years of age or older~* Accepts Healthy Volunteers~* P. falciparum parasitemia between 1,000 and 100,000 parasites/μl~* History of fever or presence of fever (temperature ≥ 37.5°C)~Exclusion Criteria~* Signs/symptoms of severe/complicated malaria~* Ingestion of various antimalarial drugs, or antibiotics in the previous 2 weeks to 2 months~* History of any drug-related hearing impairment~* Abnormal hearing function at study entry~* Exposure to sustained loud noises, by self-report, within the past 24 hours~* Present ear problems~* Pregnant or lactating (urine test for β-HCG) to be performed on any woman of child bearing age)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Artemether-lumefantrine (Coartem) (Type: EXPERIMENTAL): Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
- Atovaquone-proguanil (Malarone) (Type: ACTIVE_COMPARATOR): Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
- Artesunate-mefloquine (Type: ACTIVE_COMPARATOR): Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).